Friday, February 13, 2026

Latest

Canopy Growth: Canaccord Estimates $101.1 Million In Top Line Revenue For Q1 2021

Canopy Growth (TSX: WEED) (NYSE: CGC) will report their first fiscal quarter of 2021 on August 10th before market open with the call following at 10:00 am. With a C$2.2 billion annualized run-rate that is the Canadian market, Canaccord analyst Matt Bottomley says that COVID-19 is likely to weigh on the quarter, as sales from licensed producers to distributors have most likely been impacted more heavily than what retail data suggests.

Canaccord’s Matt Bottomley estimates are forecasting that Canopy’s recreational cannabis revenue come in at C$40.8 million, which is around C$9 million lower than the fourth fiscal quarter of C$49.7 million or an 18% decrease quarter over quarter. Meanwhile Gross Domestic Medical and Gross International Revenue are currently estimated to bet C$14.6 million and C$20.9 million, respectively, which will be flat quarter over quarter. Finally, Total Revenue totaling C$101.1 million is estimated for the quarter, C$14 million lower than last quarter’s figure or a 12% decrease quarter over quarter.

Bottomley states that even though Cannabis 2.0 sales are expected to be over 10% of total says during this quarter, due to “less favourable provincial purchasing patterns” and the closing of many of Canopy’s owned retail stores is the reasoning behind why they are forecasting C$40.8 million in revenue or a decrease of 18% quarter over quarter. Alongside forecasting flat international and Canadian medical sales quarter over quarter, Bottomley is also forecasting a 16.5% decline in Canopy’s “other” revenue streams. Management has cited that the segment has rebounded modestly from the 30% declines it saw at the start of the quarter. For these reasons, Canaccord forecasts net revenue to come in at C$94.7 million, or down 12% from last quarter.

The last thing to note is that Canaccord is forecasting Canopy’s cash position to come in around C$2 billion, as the exercise of C$245 million in warrants by Constellation Brands offsets the estimated C$225 million in operating and capital expenses for the quarter.

Currently, Canaccord has a hold rating and a C$21 price target on Canopy Growth.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Back to the Cariboo: Gold Rush History Meets Modern Discovery | Golden Caribou

Gold Prices Are High, Experience Matters | Rob McLeod

Silver Is a Wild Animal, Gold Heads for $6,000 in 2026 | Craig Hemke

Recommended

Canadian Copper Plans 2,500 Metre Drill Program For 2026

Mercado Receives Permits For Planned 3,000 Metre Drill Program At Copalito

Related News

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM

Canopy Growth Investment Results In $1.0 Billion Impairment For Constellation Brands

Canopy Growth Corp (TSX: WEED) continues to cause problems for Constellation Brands (NYSE: STZ). The...

Thursday, October 6, 2022, 09:03:23 AM

Silvercorp: Production Results Miss Canaccord Estimates

Last week, Silvercorp Metals Inc. (TSX: SVM) (NYSE: SVM) reported its operational results and announced...

Wednesday, July 21, 2021, 04:39:00 PM

Lundin Mining: BMO Maintains $13.00 Price Target Following Chapada Resumption

Yesterday Lundin Mining (TSX: LUN) announced that they had resumed full production at their Chapada...

Tuesday, December 22, 2020, 11:51:00 AM

Raymond James Calls Indiva 75% Undervalued, Gives 243% Upside Target

This week, Raymond James initiated coverage on Indiva Limited (TSXV: NDVA) with a $1.75 price...

Thursday, September 9, 2021, 03:42:00 PM